Fielder Capital Group’s Eli Lilly LLY Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$534K Buy
581
+84
+17% +$85.2K 0.12% 121
2025
Q4
$534K Buy
497
+32
+7% +$30.6K 0.11% 113
2025
Q3
$354K Buy
465
+64
+16% +$47.6K 0.08% 148
2025
Q2
$312K Sell
401
-86
-18% -$66.8K 0.08% 158
2025
Q1
$402K Buy
487
+106
+28% +$88.2K 0.12% 115
2024
Q4
$294K Sell
381
-1
-0.3% -$828 0.09% 143
2024
Q3
$338K Buy
382
+3
+0.8% +$2.7K 0.11% 123
2024
Q2
$343K Buy
379
+1
+0.3% +$800 0.13% 106
2024
Q1
$294K Sell
378
-12
-3% -$8.54K 0.13% 112
2023
Q4
$227K Buy
+390
New +$228K 0.14% 122

Other funds holding LLY

Fielder Capital Group's LLY Position: Q1 2026 in Review

Fielder Capital Group increased its Eli Lilly (LLY) stake by 17% in Q1 2026, buying an estimated $85.2K and bringing the position to 581 shares worth $534K. The position accounts for 0.12% of the portfolio, ranked #121.

Fielder Capital Group first reported a position in LLY in Q4 2023 and has held it in 10 quarters since. 4,354 funds tracked by Wall St. Rank hold LLY as of Q1 2026.

  • Fielder Capital Group held 581 shares of Eli Lilly worth $534K as of Q1 2026.
  • Fielder Capital Group bought 84 Eli Lilly shares in Q1 2026, an estimated $85.2K.
  • Eli Lilly made up 0.12% of Fielder Capital Group's portfolio in Q1 2026, its #121 holding.
  • Fielder Capital Group first reported a position in Eli Lilly in Q4 2023 and has held it in 10 quarters since.
  • 4,354 funds tracked by Wall St. Rank held Eli Lilly as of Q1 2026.

Based on Fielder Capital Group's 13F filing for Q1 2026, filed 12 May 2026.